RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1187-1195

  Danks, Lynett ^a,b   Komatsu, Noriko ^a   Guerrini, Matteo M ^a,b   Sawa, Shinichiro ^a,b   Armaka, Marietta ^c   Kollias, George ^c   Nakashima, Tomoki ^b,d   Takayanagi, Hiroshi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; TNFSF11 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE EROSION; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CELLS BY BODY ANATOMY; CONTROLLED STUDY; FIBROBLAST; HISTOPATHOLOGY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; ANIMAL; ARTICULAR CARTILAGE; BONE REMODELING; C57BL MOUSE; CD4+ T LYMPHOCYTE; CHONDROCYTE; ETIOLOGY; EXPERIMENTAL ARTHRITIS; GENE DELETION; GENETICS; IMMUNOLOGY; METABOLISM; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY; SYNOVIUM;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE REMODELING; BONE RESORPTION; CARTILAGE, ARTICULAR; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHONDROCYTES; FIBROBLASTS; GENE DELETION; MALE; MICE, INBRED C57BL; OSTEOCLASTS; RANK LIGAND; SYNOVIAL MEMBRANE;

EID: 84971634562     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-207137     Document Type: Article

References (42)

1. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
2. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
3. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
4. Quinn JM, Elliott J, Gillespie MT, et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-7.
5. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
6. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011;17:1231-4.
7. Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011;17:1235-41.
8. Fumoto T, Takeshita S, Ito M, et al. Physiological functions of osteoblast lineage and T cell-derived RANKL in bone homeostasis. J Bone Miner Res 2014;29:830-42.
9. Onal M, Xiong J, Chen X, et al. Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 2012;287:29851-60.
10. Korganow AS, Ji H, Mangialaio S, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451-61.
11. Nandakumar KS, Backlund J, Vestberg M, et al. Collagen type II ( CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res Ther 2004;6:R544-50.
12. Nandakumar KS, Holmdahl R. Collagen antibody induced arthritis. Methods Mol Med 2007;136:215-23.
13. Banda NK, Thurman JM, Kraus D, et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol 2006;177:1904-12.
14. Komatsu N, Takayanagi H. Inflammation and bone destruction in arthritis: synergistic activity of immune and mesenchymal cells in joints. Front Immunol 2012;3:77.
15. Pettit AR, Ji H, von Stechow D, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
16. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
17. Kamijo S, Nakajima A, Ikeda K, et al. Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody. Biochem Biophys Res Commun 2006;347:124-32.
18. Stolina M, Schett G, Dwyer D, et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther 2009;11:R187.
19. Horwood NJ, Kartsogiannis V, Quinn JM, et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-50.
20. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
21. Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
22. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655-62.
23. Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 2014;20:62-8.
24. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82.
25. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70.
26. Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008;205:331-7.
27. Ovchinnikov DA, Deng JM, Ogunrinu G, et al. Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. Genesis 2000;26:145-6.
28. Kawamoto S, Niwa H, Tashiro F, et al. A novel reporter mouse strain that expresses enhanced green fluorescent protein upon Cre-mediated recombination. FEBS Lett 2000;470:263-8.
29. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? II. T Cell-independent mechanisms from beginning to end. Arthritis Rheum 2002;46:298-308.
30. Martinez-Calatrava MJ, Prieto-Potin I, Roman-Blas JA, et al. RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. Arthritis Res Ther 2012;14:R149.
31. Hikosaka Y, Nitta T, Ohigashi I, et al. The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 2008;29:438-50.
32. Rossi SW, Kim MY, Leibbrandt A, et al. RANK signals from CD4(+) 3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med 2007;204:1267-72.
33. Roberts NA, White AJ, Jenkinson WE, et al. Rank signaling links the development of invariant γδ T cell progenitors and Aire(+) medullary epithelium. Immunity 2012;36:427-37.
34. Desanti GE, Cowan JE, Baik S, et al. Developmentally regulated availability of RANKL and CD40 ligand reveals distinct mechanisms of fetal and adult cross-talk in the thymus medulla. J Immunol 2012;189:5519-26.
35. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
36. Josien R, Wong BR, Li HL, et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162:2562-8.
37. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
38. Cremer I, Dieu-Nosjean MC, Marechal S, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 2002;100:3646-55.
39. Bachmann MF, Wong BR, Josien R, et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999;189:1025-31.
40. Josien R, Li HL, Ingulli E, et al. TRANCE, a tumor necrosis factor family membe, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000;191:495-502.
41. Williamson E, Bilsborough JM, Viney JL. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. J Immunol 2002;169:3606-12.
42. Loser K, Mehling A, Loeser S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006;12:1372-9.